Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

March 28, 2023 updated by: Chiesi Farmaceutici S.p.A.

Expanded Access Treatment With Open-Label Pegunigalsidase Alfa for Fabry Patients

The objective of this treatment protocol is to provide guidance to Treating Physicians who seek access to pegunigalsidase alfa for Fabry patients whose clinical condition, in the opinion of the Treating Physician, requires treatment with enzyme replacement therapy (ERT) with pegunigalsidase alfa and a) cannot be adequately treated with currently approved FDA products and/or b) are not able or willing to participate in any of the on-going clinical trials in the United States.

Study Overview

Status

Available

Conditions

Intervention / Treatment

Study Type

Expanded Access

Expanded Access Type

  • Intermediate-size Population

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • Available
        • University of Alabama-Birmingham
        • Contact:
          • Eric Wallace
    • Arizona
      • Phoenix, Arizona, United States, 85006
        • Available
        • Phoenix Children's Hospital, Inc.
        • Contact:
          • Jasmine Knoll
    • California
      • Orange, California, United States, 92868
        • Available
        • University of California Irvine
        • Contact:
          • Virginia Kimonis
      • Salinas, California, United States, 93901
        • Available
        • Central Coas Nephrology
        • Contact:
          • Barbara Rever
    • Florida
      • Jacksonville, Florida, United States, 32207
        • Available
        • University of Florida, Division of Pediatric Genetics
        • Contact:
          • Estella Mellin
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Available
        • Emory University School of Medicine
        • Contact:
          • William Wilcox
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • Available
        • University of Iowa
        • Contact:
          • John Bernat
    • Michigan
      • Grand Rapids, Michigan, United States, 49525
        • Available
        • Infusion Associates
        • Contact:
          • Khan Nedd
    • Texas
      • Dallas, Texas, United States, 75235-2208
        • Available
        • Dallas Nephrology Associates
        • Contact:
          • Ankit Mehta
    • Utah
      • Salt Lake City, Utah, United States, 84108
        • Available
        • University of Utah
        • Contact:
          • Nicola Longo
    • Virginia
      • Fairfax, Virginia, United States, 22030
        • Available
        • Lysosomal & Rare Disorder Research & Treatment Center (LRDRTC)
        • Contact:
          • Ozlem Goker-Alpan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • In the opinion of the Treating Physician, the patient cannot be adequately treated with any FDA approved drugs for Fabry and is not able to enroll in any current clinical trial for Fabry disease.
  • Patient (or legal guardian) is able to sign an informed consent prior to treatment.
  • A documented diagnosis of Fabry disease.
  • Preferably two, but at minimum 1, historical serum creatinine evaluations in the last 2 years with the latest value within the last 6 months.
  • Female patients and male patients whose co-partners are of child-bearing potential agree to use a medically acceptable method of contraception, not including the rhythm method. Acceptable methods of contraception include hormonal products, intrauterine device, or male or female condoms. Contraception should be used for 90 days after treatment discontinuation.

Exclusion Criteria:

  • Patients enrolled and currently treated in Study PB-102-F20, and patients enrolled and currently treated in Extension Study PB-102-F60
  • Patients who currently are on treatment under any other ongoing clinical trials of PRX-102
  • History of Type 1 (anaphylaxis or anaphylactoid like) life-threatening hypersensitivity during previous exposure to other ERTs which could not be handled with medication
  • Women who are breastfeeding may not participate unless they agree to stop breastfeeding.
  • Women who are currently pregnant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chiesi Farmaceutici S.p.A.

Collaborators

Chiesi USA, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 7, 2022

Primary Completion

December 7, 2022

Study Completion

December 7, 2022

Study Registration Dates

First Submitted

September 11, 2020

First Submitted That Met QC Criteria

September 11, 2020

First Posted (Actual)

September 17, 2020

Study Record Updates

Last Update Posted (Actual)

March 31, 2023

Last Update Submitted That Met QC Criteria

March 28, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PB-102-F90

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fabry Disease

Clinical Trials on Pegunigalsidase Alfa

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe